Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
Open Access
- 23 November 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 908-913
Abstract
Acquired haemophilia A (AHA) is an autoimmune bleeding disorder caused by autoantibodies blocking coagulation factor VIII (FVIII). Haemostatic management of AHA and concomitant thrombotic risk is difficult. We cover the management of a 75‐year‐old male with severe Covid‐19, a prothrombotic disease, and de novo AHA with severe muscle bleeding, a disease requiring highly thrombogenic haemostatic therapy and immunosuppression—a challenging combination. FVIII activity was measured using human and bovine reagents to differentiate between endo‐ and exogenous FVIII activity. For haemostatic control, recombinant human activated FVII was given, followed by emicizumab, as a less thrombogenic long‐term haemostatic agent. Steroids were used as initial immunosuppressive therapy. Later, rituximab was used for inhibitor eradication. No thromboembolic events occurred, and bleeding was effectively controlled. Emicizumab achieved haemostatic balance in a patient under haemorrhagic and thrombogenic conditions. Individual risk assessment is needed to guide treatment decisions in patients threatened by simultaneous bleeding and thrombosis.Keywords
This publication has 17 references indexed in Scilit:
- International recommendations on the diagnosis and treatment of acquired hemophilia AHaematologica, 2020
- Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 StudyBlood, 2020
- Cross‐reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH‐AH 01/2010 StudyJournal of Thrombosis and Haemostasis, 2019
- Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia ADrugs, 2018
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 studyBlood, 2015
- Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) RegistryBlood, 2012
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005